At Botanix, we genuinely believe in the therapeutic potential of CBD to treat serious medical conditions … and clearly we're not alone.

Last month, pharmaceutical company Pfizer announced its entry into the cannabinoid space after sharing news of its planned acquisition of clinical-stage company Arena Pharmaceuticals for a total equity value of around US$6.7 billion.

According to the official press release from Pfizer, ​​Arena holds a 'diverse and promising' portfolio, including an innovative CB2 agonist and dermatological disease candidate.

Read the story on Forbes.com

Read the official Pfizer press release

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Botanix Pharmaceuticals Ltd. published this content on 13 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 22:51:04 UTC.